Ghost Tree Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Ghost Tree Capital’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-100,000	Closed	-$1.04M	–	81
2014 Q3	$1.04M	Buy	+100,000	New	+$1.31M	0.56%	56

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ghost Tree Capital's VNDA Position: Q3 2023 in Review

Ghost Tree Capital sold out of Vanda Pharmaceuticals (VNDA) in Q3 2023, closing a stake of 31,000 shares — an estimated $204K sold.

Ghost Tree Capital first reported a position in VNDA in Q2 2015 and held it in 5 quarters. The position peaked at $4.44M in Q2 2015. 179 funds tracked by Wall St. Rank hold VNDA as of Q3 2023.

Ghost Tree Capital reported no remaining Vanda Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Ghost Tree Capital sold 31,000 Vanda Pharmaceuticals shares in Q3 2023, an estimated $204K.
Ghost Tree Capital first reported a position in Vanda Pharmaceuticals in Q2 2015 and held it in 5 quarters.
Ghost Tree Capital's Vanda Pharmaceuticals position peaked at $4.44M in Q2 2015.
179 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2023.

Based on Ghost Tree Capital's 13F filing for Q3 2023, filed 14 Nov 2023.